tiprankstipranks
Analyst Profile
Followed by 46 other investors
.
David Amsellem

David Amsellem

Piper Sandler
Wall Street Analyst
Ranked #7,316 out of 8,014 Analysts on TipRanks (#19,741 out of 21,455 overall experts)

Success Rate

41%
181 out of 438 Profitable Transactions

Average Return

-2.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied David Amsellem's ratings since 2011 and opened each position for the duration of 1 Year:
41.32% of your transactions would have been profitable with an average return of -2.9%

Stock Rating Distribution

692Ratings
63.87% Buy
29.48% Hold
6.65% Sell
Distribution of David Amsellem's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Collegium Pharmaceutical Inc.
(COLL)
Rating Type:Buy
Dates:May 10, 2017 - May 10, 2018
Gain:208.40%
The most profitable rating made by David Amsellem

David Amsellem's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Medicis Pharmaceutical
Buy
Upgraded
100%
+12.30%
1
XenoPort
Hold
Downgraded
0.00%
1
Obagi Medical Products
Hold
Reiterated
0.00%
1
Medicines Co
Buy
Initiated
0%
-8.30%
1
Cadence Pharma
Hold
Initiated
0.00%
1
Santarus
Hold
Downgraded
0.00%
1
Windtree Therapeutics
Buy
Initiated
$6.00
(1442.81% Upside)
0%
-28.10%
1
Forest Labs
Hold
Downgraded
50%
+24.40%
4
Questcor
Hold
Downgraded
100%
+25.25%
3
Salix
Hold
Downgraded
100%
+39.70%
4
List of latest recommendations made by David Amsellem. Click to expand and see David Amsellem's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More